BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Beam Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$24.19+0.72 (+3.07%)
Close on Oct 19, 2026
- Market cap
- $2.52B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Operating margin
-274.6%+552892.1 pts over 5 years
Net margin
-57.2%+810742.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +120.0% | +31.9% | +466.3% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -875.4% | -8.1% | |
| Return on assets | – | -64.0% | -6.2% | |
| Current ratio | – | 3.01 | 13.09 | |
| Capex to revenue | – | 68154.2% | 10.7% | |
| Diluted shares | – | 47M | 99M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Beam Therapeutics generated $930.34M from operations and spent $153.39M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$930.34M
Used
$153.39M
Capital expenditure$153.39M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-57.2%
×Asset turnover0.11×
×Equity multiplier1.31×
=Return on equity, FY2025-8.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -57.2% | 0.11× | 1.31× | -8.1% |
| FY2024 | -593.1% | 0.05× | 1.49× | -43.9% |
| FY2023 | -35.1% | 0.27× | 1.63× | -15.5% |
| FY2022 | -474.5% | 0.04× | 1.80× | -37.1% |
| FY2021 | -714.9% | 0.05× | 1.80× | -69.1% |
| FY2020 | -810800.0% | 0.00× | 13.67× | -875.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$79.99M
- Cash generatingOperating cash flow above zero-$345.10M
- Return on assets improvedROA up on the prior year-25.8% → -7.2%
- Earnings backed by cashOperating cash flow above net income-$345.10M vs -$79.99M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.82 → 13.09
- No dilutionShare count did not rise82M → 99M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.04 → 0.13